Abstract library

1836 results for "poorly differentiated neuroendocrine carcinoma".
#100 Mammalian target of rapamycin (mTOR) expression analysis and therapeutic approach in lung and gastroenteropancreatic poorly differentiated endocrine carcinoma (PDEC)
Introduction: PDEC clinically include gastroenteropancreatic PDEC, small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). These tumors are clinically similar and aggressive and they are usually treated with platinum compounds. mTOR signalling pathway has emerged as a promising target for well-differentiated endocrine carcinoma therapy. Because of varying behavior, PDEC are usually excluded from clinical trials employing the mTOR inhibitor RAD001.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Emilio Bajetta
Authors:
#117 Synchronous appendiceal neuroendocrine carcinoma and mucinous cystadenocarcinoma: a case report
Introduction: Appendiceal tumors with histological features of both carcinoids and adenocarcinomas are very rare. Carcinomas of the appendix are usually mucinous adenocarcinomas with a tendency to produce peritoneal pseudomyxoma and without metastatic spread until late in the disease course. Carcinoid tumors of the appendix are a common incidental finding.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Sanja Ognjanovic
Authors:
#182 Ki-67 (MIB-1) Proliferative Activity and Beta-Catenin Immunoexpression in Liver Metastases of Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Assessment of liver metastases biology features associated with cell proliferation and adhesion has a strong prognostic impact in patients with gastroenteropancreatic (GEP) neuroendocrine carcinomas.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD, PhD Vera V. Delektorskaya
Authors:
#237 Clinical Case of ACTH-secreting Thymic Carcinoma with Multiple Metastases to the Brain, Ovary and Skin
Introduction: ACTH-secreting thymic carcinoma (TC) is a rare neuroendocrine tumor which has a very aggressive course. We present a case of ACTH-producing TC in a 36-year-old woman.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Mrs Irina Komerdus
Authors:
#268 Temozolomide as 2.-3. line Treatment of Patients with Poorly Differentiated Neuroendocrine Carcinomas
Introduction: Knowledge of the clinical efficacy of treatment beyond first line of poorly differentiated neuroendocrine carcinomas (PDEC) is sparse. Temozolomide (TMZ) has shown effect in well-differentiated NET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: M.D. Ingrid Holst Olsen
Authors:
#311 Treatment and Prognosis of Patients with Poorly Differentiated Neuroendocrine Tumors
Introduction: Poorly differentiated neuroendocrine tumors (PDEC) represent less than 10% of all neuroendocrine tumors but have a poor prognosis.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Henning Grønbæk
Authors:
#331 Four-years Follow-up in a Case of Gastric Neuroendocrine Carcinoma
Introduction: Poorly differentiated neuroendocrine carcinoma has a poor prognosis, regardless of the primary site.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Catalina Poiana
Authors:
#382 Invaded, Moderately Differentiated Neuroendocrine Carcinoma of Larynx
Introduction: Neuroendocrine neoplasm is extremely unusual and rare in the larynx. It accounts for less than 1% of all laryngeal malignancies. According to the origin, this tumor can be divided into neural and epithelial groups and epithelial origin tumors are further sub-classified based on the degree of differentiation (well-, moderately and poorly differentiated).
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Shahin Nateghi
Authors:
#384 A Pilot Study on the Immunohistochemical Expression of Chromogranin and/or Synaptophysin in Moderate to Poorly Differentiated Gastroenteropancreatic Carcinomas
Introduction: Recent advances in specific treatment for neuroendocrine tumors (NETs) prompted us to reinvestigate the old phenomenon of neuroendocrine differentiation in carcinomas of the GI tract which has previously been shown to carry no prognostic significance.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr tony W Shek
Authors:
Keywords: NET, IHC
#507 Are all Metastatic Grade 3 WHO 2010 Neuroendocrine Carcinoma Poorly Differentiated?
Introduction: The WHO classification 2010 for neuroendocrine tumors (NET) defines poorly differentiated neuroendocrine carcinomas (NEC) as grade 3 (G3) according to mitoses> 20/10 HPF and/or Ki-67>20%.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Fritz-Line Vélayoudom-Céphise
Authors: